Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFFRON: savolitinib + osimertinib versus platinum doublet chemotherapy after osimertinib in EGFR-mutant, MET-positive advanced NSCLC
2024-511169-12-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of savolitinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Mar 2023; status: authorised.
02
Drugs
savolitinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511169-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511169-12-00.